Compare Amphastar Pharmaceuticals Inc (AMPH) vs Chipotle Mexican Grill, Inc. (CMG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Chipotle Mexican Grill, Inc. — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Chipotle Mexican Grill, Inc. trades at $32.22 (market cap $40.67B). The key difference: Chipotle Mexican Grill, Inc. is far larger — about 47.1× Amphastar Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.
| AMPH | CMG | |
|---|---|---|
Market Cap | $863.95M | $40.67B |
Sector | Health | Consumer Cyclical |
52-Week High | $30.81 | $44.04 |
52-Week Low | $16.87 | $28.17 |
Enterprise Value | $1.26B | $45.42B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Chipotle Mexican Grill (CMG) trades at $32.81, down 2.67% amid food safety concerns. The stock shows bearish technical signals with strong analyst support (70% buy ratings) and a $42.17 consensus target. Recent quarterly earnings consistently beat expectations, with Q2 2026 EPS of $0.33 exceeding estimates. Revenue growth remains steady, climbing from $8.6B in 2022 to $11.9B in 2025, though net income margin compressed to 11.42% in 2026 from 13.55% in 2024.
Despite strong fundamentals and analyst optimism, CMG faces near-term headwinds from salmonella outbreaks and fraud investigations. The stock's premium valuation (P/E 29.76) requires sustained execution amid operational challenges. Long-term growth trajectory remains intact, but current sentiment is cautious due to food safety issues and legal scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Chipotle Mexican Grill, Inc.
Chipotle Mexican Grill is the largest fast-casual chain restaurant in the United States, with systemwide sales of $7.5 billion in 2021. The Mexican concept is entirely company-owned, with a footprint of more than 3,000 stores, heavily indexed to the United States (though the firm maintains a small presence in Canada, the U.K., France, and Germany). Chipotle sells burritos, burrito bowls, tacos, quesadillas, and beverages, with a selling proposition built around competitive prices, high-quality food sourcing, speed of service, and convenience. The company generates its revenue entirely from restaurant sales and delivery fees.
Read more on CMG →
